Annexin Pharmaceuticals (Sweden) Insiders
ANNX Stock | SEK 0.54 0.06 12.50% |
Annexin Pharmaceuticals employs about 4 people. The company is managed by 6 executives with a total tenure of roughly 10 years, averaging almost 1.0 years of service per executive, having 0.67 employees per reported executive. Breaking down Annexin Pharmaceuticals' management performance can provide insight into the firm performance.
Ulrika Harndahl Insider Head CMC |
Anna MD Insider Chief Officer |
Annexin |
Annexin Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.568) % which means that it has lost $0.568 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0595) %, meaning that it generated substantial loss on money invested by shareholders. Annexin Pharmaceuticals' management efficiency ratios could be used to measure how well Annexin Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Annexin Pharmaceuticals Workforce Comparison
Annexin Pharmaceuticals AB is rated below average in number of employees category among its peers. The total workforce of Biotechnology industry is presently estimated at about 148. Annexin Pharmaceuticals holds roughly 4.0 in number of employees claiming about 2.7% of stocks in Biotechnology industry.
Annexin Pharmaceuticals Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Annexin Pharmaceuticals Price Series Summation is a cross summation of Annexin Pharmaceuticals price series and its benchmark/peer.
Annexin Pharmaceuticals Notable Stakeholders
An Annexin Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Annexin Pharmaceuticals often face trade-offs trying to please all of them. Annexin Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Annexin Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ulrika Harndahl | Head CMC | Profile | |
Anna MD | Chief Officer | Profile | |
Susan Suchdev | Chief Officer | Profile | |
Henrik Palm | Chief Officer | Profile | |
Anders MD | Chief Officer | Profile | |
MSc LLM | Therapy Ophthalmology | Profile |
About Annexin Pharmaceuticals Management Performance
The success or failure of an entity such as Annexin Pharmaceuticals often depends on how effective the management is. Annexin Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Annexin management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Annexin management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Annexin Pharmaceuticals AB , a biotechnology company, engages in developing drug candidates for the treatment of various cardiovascular diseases. The company was founded in 2014 and is based in Stockholm, Sweden. Annexin Pharmaceuticals is traded on Stockholm Stock Exchange in Sweden.
Please note, the imprecision that can be found in Annexin Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Annexin Pharmaceuticals AB. Check Annexin Pharmaceuticals' Beneish M Score to see the likelihood of Annexin Pharmaceuticals' management manipulating its earnings.
Annexin Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Annexin Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Annexin Pharmaceuticals within its industry.Annexin Pharmaceuticals Manpower Efficiency
Return on Annexin Pharmaceuticals Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 13M | |
Net Loss Per Executive | 8.7M |
Additional Tools for Annexin Stock Analysis
When running Annexin Pharmaceuticals' price analysis, check to measure Annexin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annexin Pharmaceuticals is operating at the current time. Most of Annexin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Annexin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annexin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Annexin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.